Rich Svinkin

Rich Svinkin currently serves as a Partner at Baker Hall Capital, a venture capital firm focused on strategic investments within the healthcare sector. Prior to transitioning into venture capital, he developed core operational and industry expertise through a series of professional roles at major pharmaceutical and biotechnology organizations. His corporate background includes significant tenure at Novartis, a multinational pharmaceutical corporation, as well as experience at Iveric Bio, a biopharmaceutical company that was subsequently acquired and now operates as an Astellas company. In addition to his professional corporate experience, his academic credentials include a Master's degree, which provides a foundational understanding for evaluating complex medical technologies and therapies. Svinkin's current focus centers on leveraging his specialized background in pharmaceuticals to identify, assess, and support emerging biotechnology portfolio enterprises as they navigate the clinical development and commercialization processes.